Tempus AI (NASDAQ:TEM) CAO Ryan Bartolucci Sells 7,062 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) CAO Ryan Bartolucci sold 7,062 shares of Tempus AI stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $75.00, for a total value of $529,650.00. Following the completion of the transaction, the chief accounting officer directly owned 60,804 shares of the company’s stock, valued at approximately $4,560,300. This represents a 10.41% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Stock Down 3.1%

Shares of NASDAQ TEM traded down $2.52 during midday trading on Friday, hitting $77.84. The stock had a trading volume of 9,310,212 shares, compared to its average volume of 7,226,184. The business’s 50 day moving average is $57.19 and its 200-day moving average is $52.90. The company has a market cap of $14.04 billion, a P/E ratio of -54.06 and a beta of 3.72. Tempus AI, Inc. has a 52 week low of $40.77 and a 52 week high of $104.32. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06.

Tempus AI (NASDAQ:TEM) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.10. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The company had revenue of $382.49 million during the quarter, compared to the consensus estimate of $379.69 million. During the same quarter last year, the firm earned ($0.22) earnings per share. The firm’s quarterly revenue was up 21.6% compared to the same quarter last year. As a group, analysts predict that Tempus AI, Inc. will post -1.38 EPS for the current year.

Tempus AI News Summary

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: CEO commentary outlining Tempus AI’s growth strategy and projected Medicare revenue has strengthened confidence that reimbursement expansion could provide a significant new revenue stream. Tempus AI Stock Roars Back 92% From July Low After CEO Lays Out Growth Plan
• Positive Sentiment: Morgan Stanley’s updated outlook reportedly incorporated additional reimbursement-driven revenue potential, helping fuel a sharp weekly advance in TEM shares and reinforcing the bullish growth narrative. Tempus AI Is Ripping 30% Higher This Week After Morgan Stanley Boosts Revenue Outlook
• Positive Sentiment: Trading momentum remains strong: shares have rebounded roughly 92% to 95% from the July low, with market capitalization moving above $14 billion. Above-average volume and elevated call-option activity indicate substantial speculative interest. Tempus AI Stock Is Soaring
• Neutral Sentiment: Analysts and market commentators are assessing whether the recent surge can continue. The rally has improved sentiment, but the sharp move also raises the risk of profit-taking and increased volatility. Strength Seen in Tempus
• Negative Sentiment: Zacks cautioned that recent earnings-estimate revision trends may not support another near-term advance, while brokerages maintain an average “Hold” rating. Tempus also remains unprofitable, making the stock particularly sensitive to valuation concerns and changes in growth expectations. Tempus AI Receives Average Hold Rating

Analyst Ratings Changes

TEM has been the subject of several recent analyst reports. BTIG Research boosted their price target on Tempus AI from $70.00 to $80.00 and gave the stock a “buy” rating in a research note on Thursday, August 20th. Needham & Company LLC reiterated a “buy” rating and issued a $75.00 price objective on shares of Tempus AI in a report on Friday, July 31st. Roth Capital initiated coverage on Tempus AI in a research report on Tuesday, September 8th. They issued a “neutral” rating and a $67.00 target price for the company. UBS Group started coverage on shares of Tempus AI in a research note on Wednesday, September 9th. They set a “neutral” rating and a $70.00 target price on the stock. Finally, Wall Street Zen raised shares of Tempus AI from a “sell” rating to a “hold” rating in a report on Saturday, July 25th. Eleven investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $69.33.

Hedge Funds Weigh In On Tempus AI

A number of institutional investors and hedge funds have recently modified their holdings of the company. Amova Asset Management Americas Inc. boosted its position in shares of Tempus AI by 23.4% in the first quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock worth $195,549,000 after purchasing an additional 821,490 shares during the period. Sumitomo Mitsui Trust Group Inc. boosted its holdings in Tempus AI by 23.4% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock worth $195,636,000 after buying an additional 821,490 shares during the period. Norges Bank purchased a new stake in Tempus AI in the 4th quarter worth $48,234,000. Franklin Resources Inc. increased its stake in Tempus AI by 27.9% in the 4th quarter. Franklin Resources Inc. now owns 1,861,782 shares of the company’s stock worth $109,938,000 after buying an additional 405,662 shares in the last quarter. Finally, Lingotto Investment Management LLP raised its holdings in Tempus AI by 45.9% during the fourth quarter. Lingotto Investment Management LLP now owns 1,143,526 shares of the company’s stock valued at $67,525,000 after acquiring an additional 359,667 shares during the period. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

About Tempus AI

Tempus AI, Inc is a healthcare technology company focused on applying artificial intelligence and data analytics to precision medicine. The company combines molecular testing, clinical data and machine learning to help physicians make more informed treatment decisions and support the development of new therapies.

Tempus provides genomic and diagnostic testing services, including testing intended to identify clinically relevant mutations and other biomarkers. Its technology platform also organizes and analyzes clinical and molecular data, while its AI-enabled tools are designed to assist healthcare professionals with patient care, research and workflow management.

The company serves healthcare providers, patients, pharmaceutical companies and biotechnology researchers, primarily in the United States.